• Founded in 1926, Peters Surgical is a France-based global manufacturer and distributor of high-quality surgical closure devices including sutures, haemostatic clips, haemostatic clamps and internal glues. The portfolio is focused on surgical specialties in the cardiovascular, visceral, and digestive urology and gynaecological surgical indication areas
  • Peters Surgical operates a fully integrated business model, including research and product development, regulatory and clinical affairs, device manufacture, distribution, commercial and after-sales service. It owns manufacturing facilities in France, Thailand, India and Germany and employs approximately 650 people worldwide
  • Eurazeo, a leading global investment group, as a majority shareholder since 2013, has enabled Peters Surgical to expand its presence in the operating room by developing organically and by acquiring new product ranges, such as haemostatic clips or surgical glue. Following numerous acquisitions, Peters Surgical has also increased its shares of direct-selling capabilities, and expanded its geographical presence in the US, Asia and key European countries (including Germany, Poland, among others)
  • In 2023, total revenues stood at €84M from sales in over 90 countries


  • DC Advisory acted as a financial advisor to Eurazeo Small-Mid Buyout and the management team of Peters Surgical
  • DC Advisory conducted a competitive process focused on trade buyers, pre-qualified for their interest in Peters Surgical


  • On March 13, 2024, Eurazeo announced the signing of an agreement to sell all the share capital of Peters Surgical to Advanced Medical Solutions Group plc, a world-leading specialist in tissue-healing technologies listed on the London Stock Exchange
  • The transaction will allow Peters Surgical to benefit from significant complementarities with Advanced Medical Solutions Group plc in terms of the combined portfolio of surgical products, of sales capabilities, commercial footprint in key territories and distribution networks
  • The transaction remains subject to the approval of French authorities for foreign direct investment control
  • This transaction demonstrates DC Advisory’s global expertise in the Medtech sector